News Celgene hopes device + drug can tackle aggressive brain tumo... Novocure's Optune will be tested alongside investigational Celgene drug marizomib.
News Head patch device Optune improves brain cancer survival Median overall survival improved from 15 months to 21 months when combined with chemotherapy.
News Electrical patch device shows promise against ovarian cancer Novocure's Optune device shown to be safe and tolerable in recurrent ovarian cancer.
R&D Reuters Pharma USA 2024 – Meruno Perugini Innovation in pharma comes in many forms, but at the end of the day what the industry cares about is results.
Digital Fixing clinical trial data management It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.